"At St. Luke's Clinic - Idaho Cardiology Associates, our team has over 150 years of combined experience in the treatment of heart disease and offers you comprehensive cardiovascular care. Clinic services include electrophysiology and arrhythmia exams and consultations, transthoracic and transesophageal echocardiograms, stress tests, and nuclear cardiology. We specialize in a wide range of procedures and interventions, including ablation, cardioversion, coronary angioplasty/stent, defibrillator implantation, heart catheterization, and pacemaker implantation. We also operate special clinics to focus on arrhythmias, pacemakers and defibrillators, anticoagulation, congestive heart failure, tobacco treatment, and lipid management."

During the past decade, St. Luke's Idaho Cardiology Associates conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's Idaho Cardiology Associates" #1 sponsor was "Boston Scientific Corporation" with 7 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "AtheroGenics" with 1 trials sponsored and "Biosensors Europe SA" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's Idaho Cardiology Associates" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "GE Healthcare" with 2 trials as a collaborator, "Astellas Pharma US, Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "IQVIA Biotech" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's Idaho Cardiology Associates" are "Cardiovascular Disease" (5 trials), "Coronary Artery Disease" (3 trials), "Heart Failure" (3 trials), "Atrial Fibrillation" (2 trials) and "Myocardial Infarction" (2 trials). Many other conditions were trialed in "St. Luke's Idaho Cardiology Associates" in a lesser frequency.

Most popular intervention types in "St. Luke's Idaho Cardiology Associates" are "Drug" (12 trials), "Device" (7 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Empagliflozin" (2 trials), "bococizumab (PF-04950615)" (2 trials), "AGI-1067" (1 trials) and "Ad5FGF-4" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's Idaho Cardiology Associates" are 19 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "St. Luke's Idaho Cardiology Associates". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in St. Luke's Idaho Cardiology Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's Idaho Cardiology Associates, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".